Amarin Corporation (AMRN) Q2 2024 earnings summary

Executive summary

• VASCEPA/VAZKEPA remains a leading therapy for cardiovascular risk reduction, supported by extensive clinical data and over 300 scientific publications, with strong positioning in Europe and Rest of World markets.

• The company is focused on maximizing global value, expanding access in Europe and China, and leveraging extended IP protection in Europe through 2039.

• U.S. business continues to generate cash and maintain IPE market leadership, but faces revenue headwinds from generic competition and the loss of a major exclusive account starting July 1, 2024.

• Operational execution and cost-saving initiatives have improved profitability, with a leadership transition completed in June 2024 as Aaron Berg became President and CEO.

• The company is prioritizing targeted patient populations, efficient resource allocation, and international partnerships to drive growth.

Financial highlights

• Q2 2024 total net revenue was $67.5M–$68M, down 16% year-over-year, mainly due to U.S. generic competition; U.S. product revenue was $43.8M–$44M.

• European net product revenue reached $3.5M–$4M, up significantly year-over-year, driven by growth in Spain, the U.K., and supply shipments to Greece and Israel.

• Licensing and royalty revenue was $20M, including a $15M milestone from China CVRR approval and a $4M non-cash payment.

• Gross margin declined to 48% from 64% year-over-year, primarily due to lower U.S. net selling prices.

• Net income was $1.5M in Q2 2024, compared to a $17.6M loss in Q2 2023; adjusted profit was $5.9M.

Outlook and guidance

• U.S. revenues are expected to decline in the second half of 2024 due to the loss of a major exclusive commercial account and ongoing generic pressure.

• Branded VASCEPA is expected to maintain market leadership in the IPE market despite competition and contract losses.

• Continued investment in European expansion is planned, with anticipated reimbursement progress in Italy and ongoing efforts in France.

• In China, NRDL listing for VASCEPA could occur by January 1, 2025, potentially unlocking significant market growth.

• Management expects current cash and investments to be sufficient to fund operations for at least one year.